Cristos Ifantides is an Ophthalmology physician. OpenAlex indexes 53 publications with 587 citations (h-index 13); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
777 Bannock St
Denver, CO 802044507
Telephone
303-436-6000Registry record last updated 21 Jul 2022.
Clinical trials
- Pupil Dilation for Treatment of IFIS
Sponsor: Denver Health and Hospital Authority
- Exploration of Pupil Dilation in Horner's Patients Taking Flomax
Sponsor: Denver Health and Hospital Authority
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
28 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Tarsus Pharmaceuticals, Inc.Program year202525 payments$133,282openpaymentsdata.cms.gov ↗
- Alcon Research LLCProgram year202511 payments$30,968openpaymentsdata.cms.gov ↗
- Johnson & Johnson Surgical Vision, Inc.Program year20255 payments$10,249openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
77.5%Prostaglandin Analog42.5%Latanoprost63%Bimatoprost31%Lumigan3%Travoprost3%Part D + Part B<11 patientsCarbonic Anhydrase Inhibitor15.9%Dorzolamide-Timolol69%Dorzolamide Hcl17%Simbrinza15%Part D≥74 patients+ 4 more classes in this area
Cardiovascular
10.9%Beta blocker10.9%Timolol Maleate100%Part D≥66 patientsMusculoskeletal
7.5%Cyclooxygenase Inhibitor7.5%Ketorolac Tromethamine100%Part D≥101 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- What guides treatment decisions in dry eye disease: Signs or symptoms?
Contact Lens and Anterior Eye
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”